

PLUVICTO (Lutetium Lu 177 Vipivotide Tetraxetan)

PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is a radiotracer (radiopharmaceutical) used to treat adults with an advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). It is indicated for cancer that:

- Has spread to other parts of the body (metastatic)
- Has already been treated with other anticancer treatments

The use of PLUVICTO involves exposure to radioactivity. Long-term exposure to radiation can increase the risk for a second cancer. The radiation in the urine can deliver unwanted dose if it collects on the skin. If you have problems with urine leakage, tell your doctor so they can work with you on ways to limit exposure from urine accidents.

Side Effects



The most common side effects are:

- Low blood counts (red blood cells, white blood cells and/or platelets)
- Tiredness or weakness
- Nausea, vomiting
- Loss of appetite
- Weight loss
- Urinary tract infection
- Abdominal pain
- Changes in bowel movements (constipation or diarrhea)



Tell your doctor **right away** if you develop any new or worsening symptoms, including:

- Tiredness or weakness that does not improve in a few days
- Pale skin
- Shortness of breath
- Bleeding or bruising more easily than normal
- Bleeding that does not stop
- Infection with symptoms such as fever, chills, sore throat or mouth ulcers

Administration of Treatment

- PLUVICTO is given approximately every 6 to 10 weeks for a total of 6 doses.
- You may withdraw consent at any time if you do not wish to proceed with the treatments. Treatment may be stopped if the disease is getting worse or if you have significant complications.

- PLUVICTO is given directly into a vein.
- Your nuclear medicine team will let you know the how long the procedure will take.
- Talk with you nuclear medicine doctor about how long you will need treatment with PLUVICTO.
- Blood tests are done before and during treatment to check your condition and to detect any side effects. Based on the results, your doctor may decide to delay, modify or stop your treatment.
- An overdose is unlikely. If this occurs, you will receive the appropriate treatment.
- A nuclear medicine scan is done approximately 24 hours after you receive PLUVICTO.
- This is to make sure the PLUVICTO are placed at the targeted sites in your body. The scan takes about 1 ½ hours to complete.
- After your treatment, the technologist will measure the amount radiation coming from your body and give you guidelines to protect yourself and others from radiation.
- If you miss an appointment, call your home clinic right away to reschedule.

Discharge Instructions

- Drink plenty of water to prevent dehydration and urinate often to remove excess radiation from your body.
- Plan to be in Nuclear Medicine for approximately 4 to 5 hours for your future treatment appointments.
- Avoid scheduling other appointments or events on the same day as your treatment day to reduce radiation to other people.
- Stay at least 3 feet away from others in your household for 2 to 3 days. Stay 3 feet away from children and pregnant women for 7 days.
- **Do not** have sex for 7 days.
- Sleep in a different bedroom from others in your household for 3 days. Sleep in a different bedroom from children for 7 days, or from pregnant women for 15 days.
- Let your nuclear medicine team know if you plan on traveling after treatment. The radiation may set off alarms in protected areas, such as the airport.
- Ask your care team about any special precautions for you or your caregiver regarding toilet use, showering, laundry, waste disposal, emergency medical assistance, unplanned hospitalization or traveling.